Claritas to acquire majority stake in Qubiotech's brain PET platform
Claritas NucMed Technologies has signed heads of terms to acquire a majority stake in Qubiotech Health Intelligence, the Galicia-based developer of the neuroCloud brain PET analysis platform. The deal, announced on 22 October 2026, brings together Claritas's FDA-cleared whole-body PET image enhancement and quantification software with Qubiotech's CE-marked neuro-imaging analytics, creating what the companies describe as a single independent software platform for quantitative PET across oncology and neurology.
The combined offering comprises three products: iPET, which enhances PET, PET/CT and PET/MRI images regardless of radionuclide; iPETcertum, which adds automated segmentation with SUV and volume quantification for oncology workflows; and neuroCloud, which delivers fully automated brain PET analysis including amyloid Centiloid scoring for all three currently approved amyloid tracers, without requiring a companion MRI scan or hand-drawn regions of interest.
The strategic rationale
The transaction is squarely aimed at a structural gap in nuclear medicine informatics. A significant share of quantitative PET software in routine hospital use is bundled into individual scanner manufacturers' ecosystems, creating friction for departments operating mixed-vendor fleets and for pharmaceutical sponsors running multi-centre trials that need consistent, reproducible measurements across sites and scanners. Claritas is positioning the combined entity as a vendor-neutral alternative with regulatory clearances across multiple jurisdictions.
Chetan Baxi, chief executive of Claritas HealthTech, said the combined portfolio would allow the company to "deliver from whole body to brain, independently of any scanner maker" at a moment when PET is shifting from a diagnostic snapshot to a repeated quantitative measurement in both cancer and Alzheimer's disease. Daniel Fernández, chief executive of Qubiotech, said the deal gives neuroCloud a proven route to US market clearance, noting that Claritas is already leading the FDA submission process for the brain platform.
neuroCloud is already CE-marked and in routine clinical use at public and private hospitals across Spain and Portugal. Claritas's iPET platform holds regulatory clearance in the United States, Brazil, Australia, Singapore and India, with CE and UKCA marks pending. The combined company will add an R&D and European operational base in Spain.
Market context and competitive landscape
The deal arrives at a particularly active moment for brain PET in clinical practice. The approvals of amyloid-targeting therapies for early Alzheimer's disease have elevated amyloid PET from a research tool to a clinical gateway, both for patient selection and treatment monitoring. That demand is generating commercial interest across the imaging software and radiopharmaceutical sectors, with established players including large scanner manufacturers and specialist neuroimaging software firms all seeking to consolidate their positions.
In oncology, the rise of theranostics, pairing PET-based patient selection with targeted radiopharmaceutical therapy, is similarly increasing demand for reproducible, quantitative PET readouts across multicentre studies. Independent software vendors that can operate across scanner brands, isotopes and indications are well-placed commercially as pharmaceutical sponsors seek to standardise imaging endpoints across large international trials.
The financial terms of the Claritas-Qubiotech transaction have not been disclosed, and the deal remains conditional on finalising definitive agreements. Investors and hospital procurement teams will be watching for confirmation of the transaction close, regulatory progress on neuroCloud's FDA filing, and the first jointly-marketed commercial contracts as early indicators of whether the combined platform can convert its broad clearance footprint into durable market share.